Skip to main content

Infanrix (DTaP) Side Effects

Generic name: diphtheria and tetanus toxoids / pertussis, acellular

Medically reviewed by Drugs.com. Last updated on Feb 5, 2024.

Note: This document contains side effect information about diphtheria and tetanus toxoids / pertussis, acellular. Some dosage forms listed on this page may not apply to the brand name Infanrix (DTaP).

Applies to diphtheria and tetanus toxoids / pertussis, acellular: intramuscular suspension.

Serious side effects of Infanrix (DTaP)

Along with its needed effects, diphtheria and tetanus toxoids/pertussis, acellular may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking diphtheria and tetanus toxoids / pertussis, acellular:

Less common

Incidence not known

Other side effects of Infanrix (DTaP)

Some side effects of diphtheria and tetanus toxoids / pertussis, acellular may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to diphtheria and tetanus toxoids / pertussis, acellular: intramuscular suspension.

Nervous system

Very common (10% or more): Irritability/fussiness (62%), drowsiness (54%), loss of appetite (27%)

Uncommon (0.1% to 1%): Persistent crying (3 or more hours)

Rare (less than 0.1%): Seizures

Postmarketing reports: Encephalopathy, headache, hypotonia, syncope[Ref]

Local

Very common (10% or more): Local redness (39%), local pain (32%), local swelling (25%)

Postmarketing reports: Injection site reaction, injection site induration[Ref]

Other

Very common (10% or more): Fever (100.4F or higher) (30%)

Postmarketing reports: Ear pain, fatigue, Sudden Infant Death Syndrome[Ref]

Hypersensitivity

Postmarketing reports: Anaphylactic reaction, hypersensitivity[Ref]

Hematologic

Postmarketing reports: Lymphadenopathy, thrombocytopenia[Ref]

Immunologic

Postmarketing reports: Bronchitis, cellulitis, respiratory tract infection[Ref]

Cardiovascular

Postmarketing reports: Cyanosis[Ref]

Dermatologic

Postmarketing reports: Angioedema, erythema, pruritus, rash, urticaria[Ref]

Respiratory

Postmarketing reports: Apnea, cough[Ref]

Frequently asked questions

More about Infanrix (DTaP) (diphtheria and tetanus toxoids / pertussis, acellular)

Patient resources

Other brands

Daptacel (DTaP), Tripedia (DTaP)

Professional resources

Other brands

Daptacel (DTaP)

Related treatment guides

References

1. Product Information. Infanrix (DTaP) Preservative Free (diphtheria/tetanus/pertussis (DTaP) ped). GlaxoSmithKline. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.